Searched for
NICOTINE SALTS
Small-cap stocks: Riskier, yes, but if picked well, risk-reward ratio favours risk-takers; 6 small-caps with upside potential of up to 45%The Q3 earnings season is likely to provide some positive surprises as it will reflect the full impact of the GST rate rejig and the softer...- You’re not fat, just manipulated: Delhi doctor proves how some foods hijack brain's reward system. What's the solution?Senior Delhi surgeon Dr. Anshuman Kaushal explains that late-night cravings and overeating are often not about hunger but a “food noise” cr...
- Calcium deficiency starts here: Study explains 'very common' overlooked factors that slowly weaken our bonesCalcium deficiency silently weakens bones. Everyday habits like skipping dairy and too much caffeine can cause it. Subtle signs like muscle...
- New GST rates from today, September 22: Check the full list to see what’s cheaper and what’s costlierNew GST Rates Full List: India's revised GST structure, effective today, reduces taxes on nearly 400 goods and services, including food, au...
- Understanding Tinnitus: How a rare condition can affect your hearing and what you need to knowTinnitus, affecting millions globally, is often linked to hearing loss but can indicate serious neurological issues. A 24-year-old woman's ...
- Pharma sector: Reasons to look at it beyond the tariff exemption. 7 pharma stocks with an upside potential of up to 43%Along with semiconductors, electronics and IT, pharma is another sector exempt from the Trump tariffs. Still, as the broader indices declin...
- Necessary pill for portfolio during volatility and Trump tariff wars: 8 pharma stocks with an upside potential of up to 48%Let’s accept the fact that we are likely to be dealing with volatility for the next four years. Both in the real world and in the global an...
- A Trump tariff tantrum-proof sector? 8 stocks from pharma sector, where Democrats and Republicans are in agreement, with an upside potential of up to 34% in 1 yearWhen Donald Trump is back in the saddle, one thing is certain: Tariff wars. Yes, China will be the biggest target. But for all those who th...
- As smog engulfs the street, essential pills for a healthy of portfolio: 5 pharma stocks with an upside potential of up to 39%Here’s a lesson from history: For a long-term investor, buying in a correcting market is mostly an opportunity. The operative part, of cour...
- On a path to recovery; 7 mid-cap pharma stocks with an upside potential up to 47 %After the covid tailwinds got over, pharma stocks witnessed a phase of under-performance. However as the markets get jittery, select pharma...
- Defensive Bets: 4 midcaps from pharma sector with ‘Buy’ & ‘Strong Buy’ ratings have upside potential of up to 31%As NIFTY gets even more volatile, there are some sectors which are traditionally considered defensive and they tend to get attention when m...
- Tobacco Harm Reduction - A Missed Public Health Opportunity for India
- ITC foraying into boutique brands; should you buy it?“ITC may fit the bill for only those investors who are happy with the dividend yield and less volatility. Otherwise we are not too excited.”
- ITC to foray into boutique lifestyle hotel segment with new brandThe conglomerate is also diversifying its flagship tobacco business into manufacturing of nicotine and nicotine salts primarily for export ...
- ITC diversifying tobacco business into manufacturing of nicotine and nicotine saltsThe conglomerate will undertake this new business through a newly set up wholly-owned subsidiary, ITC IndiVision Limited. ITC IndiVision wi...
- World COPD Day: Indoor air pollution an invisible evil; avoid incense sticks at home, have fibre-rich food & limit salt intakeCOPD causes more deaths annually than diabetes, malaria, TB and breast cancer combined.
- The many journeys of the marvellous mashed potatoFrom Joel Robuchon to ragda pattice, it's been a big mash.
- Life after a heart attack: Exercise regularly, control your stress levelsA heart attack is a serious problem and can be fatal. It is the world's number one killer
- Pfizer counters Dr Reddy’s claims against its anti-smoking drugPfizer has responded to the post-grant opposition filed by Dr Reddy’s Laboratories (DRL) against its anti-smoking drug Champix.
Load More
